It was subsequently shown to circulate in the bloodstream of ovarian cancer patients and to be more specific for cancer detection than CA125; as such, HE4 is the second FDA-approved biomarker for ovarian cancer (CA125 being the first). This evidence concerns the gene WFDC2 and ovarian cancer.